AnaptysBio (NASDAQ:ANAB) Shares Down 4.9% – Here’s Why

AnaptysBio, Inc. (NASDAQ:ANABGet Free Report) dropped 4.9% on Tuesday . The company traded as low as $32.95 and last traded at $33.03. Approximately 48,018 shares changed hands during trading, a decline of 85% from the average daily volume of 324,649 shares. The stock had previously closed at $34.74.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Truist Financial increased their target price on AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. HC Wainwright reiterated a “buy” rating and issued a $55.00 price target on shares of AnaptysBio in a research note on Wednesday, August 14th. Wedbush restated an “outperform” rating and set a $42.00 price objective on shares of AnaptysBio in a research note on Thursday, September 26th. Finally, JPMorgan Chase & Co. lifted their target price on AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.10.

Get Our Latest Report on ANAB

AnaptysBio Price Performance

The firm has a market cap of $914.91 million, a PE ratio of -5.66 and a beta of -0.29. The business has a fifty day moving average price of $35.27 and a two-hundred day moving average price of $29.02.

AnaptysBio (NASDAQ:ANABGet Free Report) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). The company had revenue of $10.97 million during the quarter, compared to analysts’ expectations of $25.85 million. AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. As a group, sell-side analysts forecast that AnaptysBio, Inc. will post -6.84 EPS for the current fiscal year.

Insider Transactions at AnaptysBio

In other news, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the sale, the insider now directly owns 15,398 shares in the company, valued at $595,440.66. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the firm’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the transaction, the insider now directly owns 15,398 shares in the company, valued at $595,440.66. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Ecor1 Capital, Llc acquired 273,972 shares of the stock in a transaction dated Wednesday, August 14th. The shares were bought at an average cost of $36.50 per share, for a total transaction of $9,999,978.00. Following the acquisition, the insider now owns 7,794,996 shares in the company, valued at $284,517,354. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 23,940 shares of company stock valued at $945,436. 33.70% of the stock is owned by insiders.

Institutional Trading of AnaptysBio

Several large investors have recently modified their holdings of the company. Ensign Peak Advisors Inc boosted its holdings in AnaptysBio by 74.4% during the second quarter. Ensign Peak Advisors Inc now owns 75,755 shares of the biotechnology company’s stock valued at $1,898,000 after acquiring an additional 32,313 shares during the period. Acadian Asset Management LLC bought a new stake in AnaptysBio during the 1st quarter valued at approximately $420,000. Susquehanna Fundamental Investments LLC acquired a new stake in AnaptysBio in the 1st quarter valued at approximately $1,221,000. Alpha DNA Investment Management LLC bought a new position in AnaptysBio in the 2nd quarter worth approximately $399,000. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of AnaptysBio by 38.2% during the second quarter. Assenagon Asset Management S.A. now owns 306,633 shares of the biotechnology company’s stock worth $7,684,000 after buying an additional 84,795 shares during the last quarter.

About AnaptysBio

(Get Free Report)

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

See Also

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.